ArticleAntimicrobial agents and chemotherapy2003
Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Cutaneous fistulization of the hydatid disease: A PRISMA-compliant systematic review.Medicine · 2016Pooled it
- Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model.PLoS neglected tropical diseases · 2026Article
- Human Alveolar Echinococcosis-A Neglected Zoonotic Disease Requiring Urgent Attention.International journal of molecular sciences · 2025Review
- Current status of drug therapy for alveolar echinococcosis.World journal of hepatology · 2024Review
- Rare presentation of hepatic alveolar echinococcosis mimicking hepatocellular carcinoma.BMJ case reports · 2024Article
- Chemotherapy for the treatment of alveolar echinococcosis: Where are we?Parasite (Paris, France) · 2024Review
- Case Report: Amphotericin B and Mefloquine as a Salvage Treatment of Alveolar Echinococcosis.The American journal of tropical medicine and hygiene · 2023Article
- Salvage Therapy for Alveolar Echinococcosis-A Case Series.Pathogens (Basel, Switzerland) · 2022Article
- [Diagnostics and management of intra-abdominal Echinococcus manifestation].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2019Review
- The importance of being parasiticidal… an update on drug development for the treatment of alveolar echinococcosis.Food and waterborne parasitology · 2019Article
- Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2018Article
- Review
- Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.PLoS neglected tropical diseases · 2018Article
- Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany.GMS infectious diseases · 2017Article
- Current status of diagnosis and treatment of hepatic echinococcosis.World journal of hepatology · 2016Review
- Repurposing drugs for the treatment and control of helminth infections.International journal for parasitology. Drugs and drug resistance · 2014Review
- Treatment of echinococcosis: albendazole and mebendazole--what else?Parasite (Paris, France) · 2014Review
- In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.Parasitology research · 2013Article
- Hepatic echinococcosis: clinical and therapeutic aspects.World journal of gastroenterology · 2012Review
- In vitro effects of some herbs used in Egyptian traditional medicine on viability of protoscolices of hydatid cysts.The Korean journal of parasitology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with alveolar echinococcosis are diagnosed at a late stage when the disease has advanced to unresectable hepatic lesions. These patients require lifelong therapy with benzimidazoles, the only medical treatment currently available. To date, no treatment option remains for patients with benzimidazole intolerance or treatment failure. Amphotericin B was recently shown to exert antiparasitic activity in vitro. Here, we report the efficacy of amphotericin B in human alveolar echinococcosis. In three patients with extensive disease and without further treatment options, disease progression had been documented over several months. They were treated with amphotericin B intravenously at a dose of 0.5 mg/kg of body weight three times per week. Follow-up parameters were physical examination, laboratory parameters, and imaging techniques. Amphotericin B treatment effectively halted parasite growth in all three patients. The antiparasitic effect was most evident by spontaneous closure of cutaneous fistulae in two patients and by constant size of parasitic lesions during treatment, as assessed radiologically. Metabolic activity in parasitic areas was visualized by positron emission tomography and significantly decreased during treatment. However, progressive affection of the heart in one patient could not be stopped. All patients currently continue on amphotericin B and have been treated for 25, 17, and 14 months, respectively. We introduce amphotericin B as salvage treatment for alveolar echinococcosis patients with intolerance or resistance to benzimidazoles, as it effectively suppresses parasite growth. Amphotericin B is not parasitocidal; therefore long-term treatment has to be anticipated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.